Robert Rifkin, MD from Rocky Mountain Cancer Center discusses development of a predictive model of multiple myeloma patient outcomes and…
Browsing: Acute Lymphoblastic Leukemia
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses baseline disease characteristics & diagnostic patterns for NDMM – observations over…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses blood biopsies instead of bone marrow and new findings from blood biopsy…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses center for prevention of progression of blood cancers and focused on precursor…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses survival and depth of response in African American and Non-AA patients…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses cases when cell free DNA is most beneficial and specific patient populations…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Connect® multiple myeloma patient registry and eventually pool data from Connect®…
Joshua Richter, MD from John Theurer Cancer Center discusses next step for Phase 1 GBR 1342 studies and identifying the…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses collaborators provide samples to Dana Farber Institute and large amount of samples…
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses this phase 3 trial has shown improved overall…
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses phase 2 trials of BCMA targeted therapy and finding…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses limitations of blood biopsy and that one must have enough circulating DNA…
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the first phase 3 trial of a new…
Joshua Richter, MD from John Theurer Cancer Center discusses inclusion and exclusion criteria of GBR 1342 and the trial designed…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses on how to improve the prediction of progression of multiple myeloma at…
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses data shows safety of drugs for clinicians & academia…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib doing patterns and the data presented for appropriate dosing of…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses advantages of blood biopsy and how blood draw is comfortable and convenient…
Joshua Richter, MD from John Theurer Cancer Center discusses GBR 1342 studies in phase 1 and search for the maximum…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses phase 2 trial of Dasatinib with Philadelphia Chromosome+ ALL and how…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses largest study on genomic smoldering Multiple Myeloma and 135 patients were studied…
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the analysis from the randomized phase 3 Aspire…
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses trial combines Daratumumab with Carfilzomib & Dexamethasone and the…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses poster #1 phase 2 study of Daratumumab+ CyBorD and the dose…
Jens Lohr, MD from Dana-Farber Cancer Institute discusses cell free DNA sequencing and DNA is isolated in the bloodstream instead…
John M Burke, MD from Rocky Mountain Cancer Centers discusses further promising studies in 2018 – CAR-T cell therapy, Polatuzumab,…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses ongoing randomized studies of Selinexor and Selinexor with chemotherapy, single-agent…
John M Burke, MD from Rocky Mountain Cancer Centers discusses CAR-T cell therapy with diffuse Large-B-cell Lymphoma and more CAR-T…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses further immunotherapy research in 2018-19 and the incorporation of new drugs…
John M Burke, MD from Rocky Mountain Cancer Centers discusses lymphoid malignancies treatment developments and replacement of Bleomycin with Brentuximab…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON – Bortezomib in combination…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses patients with Philadelphia Chromosome+ ALL can be cured and limited use…
John M Burke, MD from Rocky Mountain Cancer Centers discusses new Phase 3 Murano trial for CLL and Venetoclax &…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses individualized medicine in 2018 and therapies based on tumor…
John M Burke, MD from Rocky Mountain Cancer Centers discusses monitor patients minimal residual disease status and maintenance doses of…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses successor trials from North American and European group and testing imatnib…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses Selinexor its mechanism of action and as it restores the…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses a new oral compound, Selinexor and how it can be…
John M Burke, MD from Rocky Mountain Cancer Centers discusses a new study with diffuse large B-cell lymphoma and improvements…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses subgroups of patients who benefit from interferon and delaying…
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses high-response rates from both Selinexor and velcade and the combination…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses Phase 2 trial of dasatinib with Philadelphia Chromosome+ ALL and the…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses use of rituximab after bendamustine is relatively safe at the…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses impact of immune-based therapies and great impact on lymphoid…
Michael Kauffman, MD from Karyopharm Therapeutics Inc discusses additional combinations with Selinexor & pomalidomide, revlimid, daratumumab at the 2017 American…
Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses EsPhALL regimen and adding Dasatnib to intensive chemotherapy backbone at the…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses multiple myeloma study and added daratumumab towards CD38 at the…
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy with or without pembrolizumab (KEYTRUDA)…
Soulen – Who Should Get PRRT Weighing Cumulative Toxicity Key to PRRT Treatment Michael C. Soulen, MD of the University…